AVCN.TO - Avicanna Inc.

Toronto - Toronto Delayed Price. Currency in CAD
4.3400
-0.2900 (-6.26%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close4.6300
Open4.6300
Bid4.3300 x N/A
Ask4.3500 x N/A
Day's Range4.2500 - 4.6300
52 Week Range3.5400 - 7.4000
Volume47,210
Avg. Volume81,567
Market Cap94.98M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.8570
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Avicanna (TSX: AVCN) Enters an Exclusive Research Agreement with the University of Guelph for Proprietary Cannabinoid-based Products and Formulations to Treat Psychiatric Disorders
    CNW Group

    Avicanna (TSX: AVCN) Enters an Exclusive Research Agreement with the University of Guelph for Proprietary Cannabinoid-based Products and Formulations to Treat Psychiatric Disorders

    TORONTO , Sept. 13, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it will further the research and development and pre-clinical analysis of its proprietary prescription and over-the-counter ("OTC") cannabinoid products and formulations through an exclusive research agreement with the University of Guelph in Canada for a project to be performed by Dr. Jibran Khokhar , Assistant Professor at the University of Guelph , Ontario Veterinary College, Department of Biomedical Sciences, as principal investigator.

  • Market Exclusive

    Avicanna Working with University of Toronto and University of Guelph on Cannabinoid Research

    Avicanna (TSX: AVCN) (OTCMKTS:AVCIF), a biopharmaceutical company focused on plant-derived cannabinoid-based products, said it has expanded its research and collaboration agreement with Dr. Christine Allen's research group at the University of Toronto. Dr. Allen has stepped down as Avicanna's chief scientific officer and has joined the University of Toronto. However, she will increase her involvement […]The post Avicanna Working with University of Toronto and University of Guelph on Cannabinoid Research appeared first on Market Exclusive.

  • Avicanna (TSX: AVCN) Further Strengthens its Position as a Canadian Leader in Cannabinoid Based Research and Development with Expansion of University of Toronto Collaboration and Execution of University of Guelph Research Agreement
    CNW Group

    Avicanna (TSX: AVCN) Further Strengthens its Position as a Canadian Leader in Cannabinoid Based Research and Development with Expansion of University of Toronto Collaboration and Execution of University of Guelph Research Agreement

    TORONTO , Aug. 30, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has expanded the scope and duration of its research and collaboration agreement with Dr. Christine Allen's research group at the University of Toronto . Additionally, Dr. Allen has stepped down as Avicanna's Chief Scientific Officer, having accepted a prominent role with the University of Toronto , however, Dr. Allen will increase her involvement in Avicanna's pharmaceutical development and optimization through the expanded collaboration between Avicanna and Dr. Allen's research group.

  • Avicanna (TSX: AVCN) Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes
    CNW Group

    Avicanna (TSX: AVCN) Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes

    TORONTO , Aug. 23, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that its subsidiary, Santa Marta Golden Hemp S.A.S. ("SMGH"), has completed its first export of purified cannabidiol ("CBD") from Colombia to Canada for research and development purposes. Aras Azadian , Chief Executive Officer of Avicanna commented "We are thrilled to complete our first export and proud to be doing so into Canada . Health Canada issued three authorizations to SMGH on June 28, 2019 to allow for the import of CBD isolates and cannabis resin into Canada from Colombia for scientific purposes.

  • Avicanna Secures Canadian Cannabinoid Research Licence at its Headquarters in Toronto's Discovery District
    CNW Group

    Avicanna Secures Canadian Cannabinoid Research Licence at its Headquarters in Toronto's Discovery District

    TORONTO , Aug. 19, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has received a research licence (the "Research Licence") from Health Canada. The Research Licence will allow Avicanna's research and development team to work with cannabinoid-based formulations and advanced pharmaceutical drug development at Avicanna's research and development headquarters located at the MaRS Discovery District in Toronto .

  • Avicanna Reports Second Quarter 2019 Financial Results
    CNW Group

    Avicanna Reports Second Quarter 2019 Financial Results

    Avicanna Reports Second Quarter 2019 Financial Results

  • Avicanna announces joint venture with Sigma Analytical Services Inc., to establish the first GMP/GLP level cannabis quality assurance laboratory in South America
    CNW Group

    Avicanna announces joint venture with Sigma Analytical Services Inc., to establish the first GMP/GLP level cannabis quality assurance laboratory in South America

    TORONTO , Aug. 8, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into an agreement with Sigma Analytical Services Inc. ("Sigma Analytical") to establish a joint venture for the testing of cannabis and cannabis-based products in Colombia . The joint venture will leverage Sigma Analytical's expertise, methodology, and intellectual property in cannabis and derived product testing to establish a laboratory to test cannabis genetics and products. Independent analytical services will be managed and operated by an operating company with complete adherence to techniques and procedures developed and implemented by Sigma Analytical.

  • Avicanna Announces Commencement of Clinical Trials for Derma-Cosmetics
    CNW Group

    Avicanna Announces Commencement of Clinical Trials for Derma-Cosmetics

    TORONTO , July 24, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the commencement of phase I clinical trials on three of its derma-cosmetic products. Centro de Atención e Investigación Médica CAIMED S.A.S. ("CAIMED") has commenced clinical studies on Avicanna's Pura Earth™ derma-cosmetics products in order to demonstrate their effectiveness with specific cosmetic endpoints, such as reduction of fine lines associated with aging, efficacy as a moisturizer for eczema prone skin, and reduction of sebum and redness attributed to acne. In connection with such clinical studies, CAIMED is currently in the process of recruitment for the Company's intensive conditioner trial for eczema prone skin and expects recruitment for the clear skin and regenerative serum trials to begin in August, with a total of 54 patients expected to be recruited per trial.

  • Avicanna Inc. Opens the Market
    CNW Group

    Avicanna Inc. Opens the Market

    Avicanna Inc. Opens the Market

  • Avicanna Commences Trading on the TSX Under the Symbol "AVCN"
    CNW Group

    Avicanna Commences Trading on the TSX Under the Symbol "AVCN"

    TORONTO , July 18, 2019 /CNW/ - Avicanna Inc. ("Avicanna") a company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its common shares commenced trading on the Toronto Stock Exchange (the "TSX") under the symbol "AVCN" at market open today, July 18, 2019 . In connection with its first day of trading, Avicanna participated in market open ceremonies at the TSX. Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

  • Avicanna Announces TSX Listing Date
    CNW Group

    Avicanna Announces TSX Listing Date

    TORONTO , July 16, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") a company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its common shares ("Common Shares") are expected to commence trading on the Toronto Stock Exchange (the "TSX") on Thursday, July 18, 2019 under the symbol "AVCN". The listing represents the first direct listing on the TSX by a company with Colombian-based cannabis cultivation assets. In connection with its first day of trading, Avicanna will be participating in market open ceremonies at the TSX, which will be broadcast live on the Business News Network morning show and live streamed on YouTube.